Resolvyx Pharmaceuticals - 2008 Fierce 15

Resolvyx Pharmaceuticals 

Based: Bedford, MA
Founded: 2005

The Scoop: Hoping to take a page from Sirtris' successful play book, Resolvyx is taking an active ingredient from nature and engineering it into a therapeutic with a long lineup of potential applications. And it has some of the world's top scientists advising it. Researchers are off to a fast start on the way to proof-of-concept data.  

What makes it Fierce: Platform technologies are favored by a whole host of venture capital firms, and that's one reason why Resolvyx has successfully captured a lineup of A-list investors that includes Biogen Idec.  

The biotech company is advancing the scientific work of Charles Serhan, an investigator at Brigham and Women's Hospital. His insight that resolvins, derived from omega-3 fatty acids, could play a role as a key mediator for inflammatory conditions has earned $42 million in the first two rounds for the company. And the tonic nature of resolvins has been compared to resveratrol in red wine, which has made Sirtris' fortune. 

Proof-of-concept data is expected to start flowing this year, and the company has the capital to keep it pumping into the third quarter of next year, when it will have plenty of insight into the efficacy of resolvins for eye disease and systemic inflammation. And researchers have highlighted early indications of efficacy for wet, age-related macular degeneration, raising the possibility of a topical application.  

Success at this stage would open up new research opportunities in a host of disease categories, including programmed cell death. 

What to look for: Mid-stage data. If Resolvyx can make a convincing case for resolvins, the versatility of the drug platform opens up new prospects for collaborations and keeps investors coming back for more. There could even be an IPO in the cards, if the markets and the data can align. 

The 2008 Fierce 15 is brought to you by Quintiles

Resolvyx Pharmaceuticals - 2008 Fierce 15

Suggested Articles

Two months of treatment with the diabetes drug Jardiance reduced pulmonary congestion and biomarkers of heart failure in pig models.

Neither dose of the NGF inhibitor hit all the co-primary efficacy goals, and both fared worse than placebo on the safety assessments.

Mustang Bio’s stock leapt more than 400% before settling down, on the news that its gene therapy cured eight infants with “bubble boy” syndrome.